Position in SYRE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,291,837
+$1,261,674 QoQ
Shares Held
14,551
+2333.3% QoQ
Ownership
0.017%
of shares outstanding
% of Portfolio
0.30%
of 13F equity value
Holder Rank
#148
of 265 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Neo Ivy Capital Management holds $15,852,316 across 14 Biotechnology names. SYRE ranks #6 (8.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MIRM |
Mirum Pharmaceuticals, Inc.
|
35,826 | $4,194,149 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
10,195 | $2,495,430 | |
| 3 | VERA |
Vera Therapeutics, Inc.
|
48,937 | $2,099,886 | |
| 4 | IMNM |
Immunome Inc.
|
80,876 | $1,713,762 | |
| 5 | APGE |
Apogee Therapeutics, Inc.
|
9,798 | $1,300,488 | |
| 6 | SYRE |
Spyre Therapeutics, Inc.
This page
|
14,551 | $1,291,837 | |
| 7 | TECH |
BIO-TECHNE Corp
|
11,316 | $799,475 | |
| 8 | DYN |
Dyne Therapeutics, Inc.
|
31,440 | $698,282 |
All Filings in SYRE
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,291,837 | 14,551 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $30,163 | 598 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $598,230 | 18,261 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||